Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
68 hedge funds and large institutions have $16.3M invested in Lumos Pharma, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 12 closing their positions.
1% more capital invested
Capital invested by funds: $16.1M → $16.3M (+$149K)
0% more funds holding
Funds holding: 68 → 68 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
76% less call options, than puts
Call options by funds: $294K | Put options by funds: $1.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$445K |
| 2 |
RCM
Requisite Capital Management
Dallas,
Texas
|
+$383K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$195K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$145K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$91.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$380K |
| 2 |
Millennium Management
New York
|
-$314K |
| 3 |
Goldman Sachs
New York
|
-$307K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$294K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$217K |
LUMO Hedge Fund Activity: Q3 2019 in Review
68 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2019, worth a combined $16.3M — up 0.92% from $16.1M a quarter earlier.
Fund positioning in LUMO was balanced in Q3 2019: 12 funds opened new positions, 12 closed out, 11 added to existing stakes and 19 trimmed.
The largest buyer was Eversept Partners, opening a new position worth an estimated $445K. The largest seller was Northern Trust, cutting an estimated $380K.
- 68 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $16.3M of Lumos Pharma, Inc. Common Stock stock for Q3 2019, up 0.92% quarter-over-quarter.
- 12 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2019 and 12 closed out, a net change of 0 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2019 was Eversept Partners, an estimated $445K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2019 was Northern Trust, an estimated $380K sold.
Based on aggregated 13F filings for Q3 2019.